Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $46.83 Consensus Target Price from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned a consensus rating of “Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $52.14.

A number of brokerages have recently weighed in on DNTH. Wedbush restated an “outperform” rating and issued a $36.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Guggenheim reaffirmed a “buy” rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday. Finally, TD Cowen began coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company.

Institutional Trading of Dianthus Therapeutics

A number of large investors have recently made changes to their positions in the company. R Squared Ltd acquired a new position in Dianthus Therapeutics during the fourth quarter worth approximately $26,000. Quest Partners LLC increased its holdings in shares of Dianthus Therapeutics by 112,400.0% in the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in Dianthus Therapeutics in the 4th quarter valued at $33,000. KBC Group NV purchased a new stake in Dianthus Therapeutics in the 4th quarter valued at $35,000. Finally, BNP Paribas Financial Markets acquired a new stake in Dianthus Therapeutics during the 4th quarter worth $59,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

DNTH stock opened at $21.33 on Wednesday. The business’s 50-day moving average is $22.61 and its two-hundred day moving average is $24.92. The firm has a market capitalization of $631.30 million, a P/E ratio of -8.53 and a beta of 1.82. Dianthus Therapeutics has a 1 year low of $18.13 and a 1 year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million for the quarter, compared to analyst estimates of $1.40 million. On average, analysts expect that Dianthus Therapeutics will post -2.61 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.